Stock screenerAll disclosures → EDGAR →
INTS
Conviction 51HealthcareScan · Fri, Jun 26, 2026Bullish engulfing
INTS$4.10+0.49%
ResistanceSupportVol 14Vol MA14 87.47K
Mar 27Apr 15May 4May 20Jun 9Jun 26
INTENSITY THERAPEUTICS, INC.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.intensitytherapeutics.com ↗
Price4.10
Change+0.49%
Gap-0.74%
Rel volume11.13×
Avg volume73.5K
Avg $ vol297.22K
SMA 203.94
SMA 504.57
SMA 2002.61
Price vs 50-10.23%
Price vs 200+56.99%
MA stackmixed
50/200 cross—
Supertrenddown · 4.35
RSI (14)48
MACD hist0.08
MACD crossbull · 5d
Stoch %K / %D94 / 94
ADX (14)28
+DI / −DI15 / 16
RSI divergence—
MACD divergence—
ATR %+5.68%
ADR %5.92%
52w high7.95
52w low0.2234
From 52w high-48.43%
Above 52w low+1735.27%
New 52w highNo
SqueezeOff
Bollinger width23.20%
%B0.68
Donchian pos54.63%
Donchian high4.59
Donchian low3.51
AVWAP (52w high)5.02
vs AVWAP high-18.36%
AVWAP (52w low)0.9990
vs AVWAP low+310.40%
OBV trendUp
Chaikin MF (20)0.21
Today vs 20d11.13×
Avg vol (14d)87.47K
Avg vol (20d)73.5K
Avg $ vol (20d)297.22K
Market cap—
RS 3m (vs SPY)-47.85%
RS 6m (vs SPY)+871.19%
RS line new highNo
Trend template5/8
Technical rank70.1
1 week+4.59%
1 month-8.07%
3 months-32.90%
6 months+880.86%
1 year+1295.51%
YTD+907.37%
P/E-0.94
P/B1.09
P/S—
P/FCF—
EPS-8.56
Div yield—
ROE-116.30%
ROA-94.43%
Debt/Eq—
Current4.86
EV/EBITDA—
Gross margin—
Net margin—
Rev growth—
EPS growth28.66%
Price target—
Target upside—
Analyst rating—
Institutional—
Ent. value674.39K
Revenue—
Net income-2.43M
Gross profit—
Free cash flow—
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out2.7M
Employees7
ListedFri, Jun 30, 2023
Free float—
Float %—
Short interest—
Days to cover—
Short volume—
Squeeze score—
Next earnings—
EPS forecast—
Last EPS vs est—
Last surprise—
Setup gradeC
Conviction51 / 100
Pattern quality—
Tech rank70.1 / 100
Group rank50 / 100
Status lane—
Setup direction—
Pattern family
Resistance—
Support—
Days since event—
Candle confirmBullish engulfing
News sentiment—
Financials as of Tue, Mar 31, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in INTS
No recent disclosed trades by Congress in INTS. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in INTS
No recent insider (Form 4) filings in INTS. Insiders must file within two business days of a trade.
SEC filings
EDGAR filings in INTS · 1 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.
Start free — 7-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.